Table 1.
Characteristics of patients with MM
| Total patients (males/females), n | 48 (29/19) |
| Age, median (range), y | 83 (59-92) |
| Smoldering myeloma/active myeloma | 9 (18.7)/39 (81.2) |
| Receiving treatment for active myeloma, yes/no, n | 35/4 |
| Line of therapy, if on treatment (n = 35) | |
| First | 15 (42.9) |
| Second | 10 (28.6) |
| Third | 4 (11.4) |
| Greater than third | 6 (17.1) |
| Type of therapy | |
| PI+IMiD combos | 9 (25.7) |
| VRD | 6 |
| IRD | 2 |
| PomVD | 1 |
| IMiD-based regimens | 14 (40.0) |
| Rd | 10 |
| R maintenance | 2 |
| RCd | 1 |
| PomCd | 1 |
| PI-based regimens | 2 (5.7) |
| VD | 1 |
| ICD | 1 |
| Anti-CD38 mAb-based therapies | 8 (22.8) |
| Daratumumab monotherapy | 4 |
| Daratumumab-Rd | 2 |
| Daratumumab-PomDex | 1 |
| Isatuximab-Rd | 1 |
| Belantamab mafodotin monotherapy | 2 (5.7) |
Unless otherwise noted, data are n (%).
ICD, ixazomib, cyclophosphamide and dexamethasone; IMiD, immunomodulatory drug; IRD, ixazomib, lenalidomide, and dexamethasone; mAb, monoclonal antibody; PI, proteasome inhibitor; PomCd, pomalidomide, cyclophosphamide, and dexamethasone; PomVD, pomalidomide, bortezomib, and dexamethasone; PomDex, pomalidomide and dexamethasone; R, lenalidomide; RCd, lenalidomide, cyclophosphamide, and dexamethasone; Rd, lenalidomide and dexamethasone; VD, bortezomib and dexamethasone; VRD, bortezomib, lenalidomide and dexamethasone.